A comprehensive reference covering modafinil's pharmacology, FDA-approved indications, dosage parameters, safety profile, drug interactions, and how to access it legally in the United States.
Medically reviewed by a Licensed Clinical Pharmacist | Last updated: June 2026 | References listed at end of article
| Generic Name | Modafinil |
| Brand Names | Provigil (USA) · Alertec (Canada) · Modiodal (Europe/Australia) |
| Drug Class | Eugeroic / Wakefulness-Promoting Agent |
| FDA Approval | Yes — 1998 (narcolepsy, OSA, shift work sleep disorder) |
| DEA Schedule | Schedule IV Controlled Substance |
| Standard Adult Dose | 200 mg once daily (morning) |
| Half-Life | 12–15 hours |
| Onset of Action | 30–60 minutes |
| Related Compound | Armodafinil (Nuvigil) — R-enantiomer of modafinil |
| Dependence Risk | Low to moderate (significantly lower than Schedule II stimulants) |
| Generic Available | Yes — widely available in the USA since 2012 |
Modafinil is a prescription wakefulness-promoting agent — a pharmacological class known as a eugeroic — developed in France in the 1970s and approved by the U.S. Food and Drug Administration in 1998 under the brand name Provigil. Unlike conventional stimulants such as amphetamines, modafinil promotes sustained alertness without producing the intense euphoria, cardiovascular strain, or pronounced rebound fatigue associated with classical central nervous system stimulants. This distinct profile represented a significant advancement in the pharmacological management of excessive daytime sleepiness.
Modafinil belongs to the benzhydryl sulfinyl acetamide class of compounds and is classified as a Schedule IV controlled substance in the United States. It is FDA-approved for three specific conditions: narcolepsy, obstructive sleep apnea (OSA) with residual sleepiness despite adequate CPAP use, and shift work sleep disorder (SWSD). It is additionally studied and prescribed off-label for conditions including ADHD, cognitive fatigue in multiple sclerosis, augmentation of antidepressant therapy, and jet lag management.
Following patent expiration, generic modafinil became widely available in the United States from 2012 onward, significantly reducing the cost burden for patients. The related compound armodafinil (Nuvigil) — the purified R-enantiomer of modafinil, approved by the FDA in 2007 — represents the subsequent refinement of the same pharmacological class.
Modafinil is FDA-approved and legally available in the United States by prescription only. It is classified as a Schedule IV controlled substance under the Controlled Substances Act, placing it in the same scheduling category as diazepam and tramadol — drugs recognized to have therapeutic value alongside a defined, though relatively limited, potential for abuse and dependence.
A valid prescription issued by a licensed U.S. physician or advanced practice provider is required to obtain modafinil legally from any regulated U.S. pharmacy, whether in person or via a licensed telehealth platform. While modafinil is offered without prescription through numerous online sources operating outside the U.S. regulatory framework, importing prescription controlled substances without a valid U.S. prescription is prohibited under federal law and carries serious risks including counterfeit products, incorrect dosages, and unknown adulterants.
Modafinil requires a valid U.S. prescription. Purchasing from unregulated online vendors — whether domestic or international — is illegal, exposes the patient to unverified product quality, and carries potential federal import violations. Always obtain modafinil through a licensed prescriber and a pharmacy verified by the National Association of Boards of Pharmacy (NABP) or equivalent regulatory body.
Modafinil is a racemic compound, consisting of two mirror-image molecular forms: the R-enantiomer and the S-enantiomer. Armodafinil (Nuvigil), FDA-approved in 2007, is the isolated R-enantiomer of modafinil — the pharmacologically more active of the two forms. The relationship mirrors that between other racemic drugs and their purified single-isomer successors.
| Feature | Modafinil (Provigil) | Armodafinil (Nuvigil) |
|---|---|---|
| Chemical form | Racemic mixture (R + S enantiomers) | R-enantiomer only |
| FDA Approval | 1998 | 2007 |
| Standard Dose | 100–200 mg once daily | 50–150 mg once daily |
| Half-Life | 12–15 hours | ~15 hours |
| Peak Concentration | 2–4 hours post-dose | ~2 hours (sharper peak) |
| Afternoon coverage | Declines through afternoon | Higher concentrations sustained later in day |
| DEA Schedule | Schedule IV | Schedule IV |
| Approved Indications | Narcolepsy, OSA, SWSD | Narcolepsy, OSA, SWSD |
| Generic Available | Yes (since 2012) | Yes (since 2016) |
The primary clinical distinction is that armodafinil achieves higher plasma concentrations during the mid-to-late afternoon compared to an equivalent dose of modafinil — potentially providing more consistent wakefulness coverage during critical afternoon working hours. Modafinil's concentration peaks earlier and declines faster, which some patients find preferable as it produces less interference with nighttime sleep onset. The choice between the two is largely individual, guided by the patient's specific sleep-wake needs and physician recommendation.
| Medication | Class | Half-Life | Primary Indication | Dependence Risk | DEA Schedule |
|---|---|---|---|---|---|
| Modafinil (Provigil) | Eugeroic | 12–15 hr | Narcolepsy, OSA, SWSD | Low–Moderate | Schedule IV |
| Armodafinil (Nuvigil) | Eugeroic (R-enantiomer) | ~15 hr | Narcolepsy, OSA, SWSD | Low–Moderate | Schedule IV |
| Solriamfetol (Sunosi) | Dopamine/NE reuptake inhibitor | ~7 hr | Narcolepsy, OSA | Moderate | Schedule IV |
| Pitolisant (Wakix) | H? receptor antagonist/inverse agonist | 10–12 hr | Narcolepsy (incl. cataplexy) | Low | Not scheduled |
| Amphetamine salts (Adderall) | Central stimulant | 10–13 hr | ADHD, narcolepsy | High | Schedule II |
| Methylphenidate (Ritalin) | Central stimulant | 2–4 hr | ADHD, narcolepsy | High | Schedule II |
| Sodium oxybate (Xyrem) | CNS depressant (GHB) | 0.5–1 hr | Narcolepsy with cataplexy | High | Schedule III/I |
Modafinil and armodafinil occupy a distinct clinical position: they offer meaningful wakefulness promotion without the cardiovascular load, abuse liability, or post-dose rebound characteristic of Schedule II stimulants, making them the preferred first-line pharmacological option for most cases of narcolepsy and OSA-related daytime sleepiness in clinical guidelines. Pitolisant represents a newer, non-scheduled alternative particularly relevant for patients where even Schedule IV agents are contraindicated or not tolerated.
Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy (sudden muscle weakness triggered by emotion), sleep paralysis, and disrupted nocturnal sleep. Modafinil is established as a first-line pharmacological treatment for the daytime sleepiness component of narcolepsy, with multiple randomized controlled trials confirming significant reductions in the Epworth Sleepiness Scale score and maintenance of wakefulness test performance compared to placebo. It does not address cataplexy — patients with prominent cataplexy typically require additional agents such as sodium oxybate or pitolisant.
In patients with OSA who continue to experience clinically significant excessive daytime sleepiness despite adequate and verified CPAP therapy, modafinil is approved as an adjunctive treatment. It is not a substitute for CPAP, and prescribing guidelines are explicit that the underlying OSA must remain under active treatment. A 2019 Cochrane systematic review of modafinil in OSA found statistically significant improvements in sleepiness scores and patient-reported outcomes compared to placebo, with a manageable adverse effect profile.
Shift work sleep disorder affects an estimated 10–38% of shift workers, producing excessive sleepiness during scheduled work periods and difficulty sleeping during available rest time — a pattern associated with elevated occupational accident rates and impaired cardiovascular health over time. Modafinil taken approximately one hour before the start of a night or rotating shift significantly improves wakefulness, performance accuracy, and reduces accident risk, without the prolonged post-shift insomnia associated with traditional stimulants.
Modafinil is one of the most extensively studied off-label compounds in psychiatry and neurology. Physician-supervised off-label use includes: ADHD in adults who have not tolerated or responded to first-line stimulants; cognitive fatigue associated with multiple sclerosis; augmentation of antidepressant treatment in patients with residual fatigue or partial response; cancer-related fatigue; and jet lag. A 2015 meta-analysis published in European Neuropsychopharmacology found that modafinil improved cognitive performance on measures of planning, decision-making, and learning in non-sleep-deprived healthy subjects — findings that have driven significant research interest in its broader neurocognitive applications.
Off-label prescribing of modafinil for any indication requires physician assessment, a valid prescription, and ongoing monitoring. Self-medicating with modafinil obtained outside the prescription system is both illegal in the USA and clinically unsafe, as the medication's interactions and contraindications require professional evaluation.
Modafinil's precise mechanism of action is not fully characterized — a distinction from classical stimulants whose mechanisms are well defined — and appears to be genuinely multi-modal. Its primary established mechanism is inhibition of the dopamine transporter (DAT), which increases synaptic dopamine concentrations in a controlled, sustained manner. Critically, this dopaminergic activity also promotes activity in the downstream histamine and orexin (hypocretin) systems — the brain's primary wakefulness-maintaining pathways — without producing the sharp neurochemical spike-and-crash associated with amphetamine-class agents.
The orexin system connection is clinically relevant to narcolepsy: the condition arises from the progressive loss of orexin-producing neurons in the hypothalamus, and modafinil's ability to activate orexin pathway activity provides partial pharmacological compensation for this deficit. This same neurochemical selectivity is widely understood to underlie modafinil's significantly lower abuse potential relative to classical stimulants, despite comparable wakefulness-promoting efficacy at the clinical level.
After oral administration, modafinil reaches peak plasma concentrations within 2 to 4 hours. Its half-life of 12 to 15 hours means a single morning dose provides coverage across the active waking day without substantially impairing nighttime sleep onset in most patients — a practical advantage over longer-acting traditional stimulants. The medication is extensively metabolized in the liver, primarily via CYP3A4 and to a lesser degree CYP2C19, with inactive metabolites excreted renally.
Modafinil dosing is indication-specific. Across all approved uses, the prescribing principle is consistent: use the lowest dose that achieves the therapeutic objective. Doses above 200 mg do not reliably produce additional wakefulness benefit but increase the incidence and severity of adverse effects.
| Adults — Narcolepsy / OSA | 200 mg once daily, taken in the morning. May be split as 100 mg morning + 100 mg early afternoon if tolerability requires. Maximum: 400 mg/day (rarely provides added benefit). |
| Adults — Shift Work Sleep Disorder | 200 mg taken approximately one hour before the start of the work shift. Not taken on a fixed morning schedule. Avoid use on non-shift days unless directed by physician. |
| Elderly Patients (65+) | 100 mg once daily as starting dose. Maximum 200 mg/day. Slower hepatic clearance requires dose reduction and monitoring for excessive stimulation or agitation. |
| Severe Hepatic Impairment | 100 mg once daily. Modafinil clearance is significantly reduced; standard doses produce markedly elevated blood levels in this population. |
| Renal Impairment | No formal dose adjustment required. Monitor closely in severe renal impairment; limited pharmacokinetic data available in this population. |
| Children and Adolescents (<17) | Not recommended. Safety and efficacy have not been established in pediatric populations. Narcolepsy in pediatric patients is managed through specialist referral. |
Never exceed the prescribed dose or take a second dose on the same day to compensate for a perceived reduction in effect. If the medication appears to be losing efficacy over time, this should be discussed with the prescribing physician — dose escalation without medical guidance significantly increases adverse effect risk and potential for dependence.
Modafinil is generally well tolerated at the standard 200 mg dose, particularly when taken in the morning as directed. The majority of adverse effects are mild to moderate, dose-dependent, and often resolve within the first two to three weeks as the body adjusts to the medication.
Headache is the single most frequently reported adverse effect, occurring in approximately 34% of patients in clinical trials. It is typically manageable with adequate hydration and consistent dosing timing. Nausea is the second most common complaint, usually transient and reduced by taking modafinil with food, though this is not required for absorption. Anxiety and nervousness are reported in a proportion of patients, particularly those with pre-existing anxiety predisposition or those taking modafinil later in the day. Insomnia when it occurs is nearly always a timing issue — patients who take modafinil after approximately 10 AM risk significant delay in sleep onset given the medication's 12–15 hour half-life. Strict morning dosing is the most effective preventive measure. Decreased appetite, dry mouth, dizziness, and rhinitis are among the other effects reported at lower frequencies in clinical trials.
Modafinil carries an FDA warning for serious and potentially life-threatening dermatological reactions, including Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These reactions — while rare — have been reported primarily within the first five weeks of treatment. Any new skin rash, blistering, peeling, oral sores, or fever during modafinil treatment requires immediate discontinuation and same-day medical evaluation. The medication must not be restarted without explicit physician guidance following any rash during treatment.
Modafinil can precipitate or exacerbate psychiatric symptoms in susceptible individuals. Reports include mania, hallucinations, delusions, paranoia, and aggression — in some cases occurring in patients without prior psychiatric history. Patients with a diagnosed history of psychosis, bipolar disorder, or severe anxiety disorder require careful physician assessment of the risk-benefit profile before modafinil is prescribed, and close monitoring throughout treatment. Any significant change in mood, thought content, or behavior during treatment must be reported to the prescribing physician promptly.
Modafinil produces modest, dose-dependent increases in heart rate and systolic blood pressure in a proportion of patients. While these changes are generally clinically insignificant in otherwise healthy adults, modafinil is not recommended for patients with serious cardiac arrhythmias, recent myocardial infarction, or unstable angina without explicit review by both a cardiologist and the prescribing physician. A baseline cardiovascular assessment is advisable in older patients or those with established cardiac risk factors before initiating treatment.
A small number of cases of multi-organ hypersensitivity reactions have been reported with modafinil, typically presenting as fever, rash, and dysfunction across multiple organ systems (liver, kidney, hematologic). Any systemic hypersensitivity presentation during modafinil therapy warrants immediate discontinuation and urgent evaluation.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Hormonal Contraceptives | Modafinil induces CYP3A4, accelerating contraceptive metabolism | Plasma contraceptive levels reduced by up to 50%; risk of contraceptive failure and unintended pregnancy | Use reliable non-hormonal or barrier contraception during treatment and for one full month after stopping modafinil |
| CYP2C19 Substrates | Modafinil inhibits CYP2C19 enzyme activity | Elevated plasma levels of co-administered CYP2C19 substrates (diazepam, phenytoin, omeprazole, warfarin, some antidepressants) | Monitor drug levels and clinical effects; dose adjustments of the co-administered drug may be required |
| CYP3A4 Inhibitors | Inhibition of modafinil's primary metabolic pathway | Increased modafinil plasma concentrations; potential for enhanced adverse effects | Examples: ketoconazole, itraconazole, erythromycin. Disclose to prescriber; monitor for increased side effects |
| CYP3A4 Inducers | Accelerated modafinil metabolism | Reduced modafinil plasma concentrations; potential for reduced therapeutic efficacy | Examples: rifampicin, carbamazepine, phenytoin. Dose adjustment may be required |
| MAO Inhibitors | Additive monoaminergic activity | Risk of serious hypertensive crisis and CNS toxicity | Contraindicated; allow adequate washout period (at minimum 14 days for irreversible MAOIs) before initiating modafinil |
| Other Stimulants | Additive dopaminergic and adrenergic effects | Increased cardiovascular strain (hypertension, arrhythmia); heightened anxiety and insomnia risk | Avoid concurrent use of amphetamines, methylphenidate, or other stimulant agents unless under close specialist supervision |
| Alcohol | Unpredictable CNS interaction | Alcohol may blunt modafinil's wakefulness effect while impairing judgment; cognitive impairment disproportionate to alcohol intake reported | Avoid alcohol on any day modafinil is taken |
The interaction between modafinil and hormonal contraceptives is among the most clinically significant and underappreciated drug interactions associated with this medication class. All patients of childbearing potential must be informed of this interaction before starting modafinil, and must use effective non-hormonal or barrier contraception during the entire course of treatment and for a minimum of one full month after the final dose. This applies to all hormonal contraceptive methods, including combined oral pills, progestin-only pills, patches, implants, and hormonal IUDs.
Hypersensitivity: Modafinil is absolutely contraindicated in patients with a known hypersensitivity to modafinil or armodafinil, including any prior history of Stevens-Johnson Syndrome or DRESS triggered by either compound.
Children and adolescents under 17: Safety and efficacy data are insufficient to support prescribing. Pediatric narcolepsy is managed through specialist referral using alternative approaches.
Pregnancy: The FDA assigns modafinil to Pregnancy Category C, indicating animal studies have shown fetal harm and there are no adequate controlled studies in pregnant women. Modafinil should be used during pregnancy only if the potential benefit clearly justifies the potential fetal risk, as determined explicitly by the treating physician. Effective contraception is mandatory for all patients of childbearing potential, as outlined above.
Breastfeeding: Modafinil and its primary metabolite modafinil acid are excreted in breast milk. The decision to discontinue breastfeeding or modafinil should be made in consultation with the physician, weighing the importance of the drug to the mother.
Serious cardiovascular disease: Patients with recent myocardial infarction, unstable angina, or clinically significant cardiac arrhythmias should not receive modafinil without explicit cardiologist review.
Severe hepatic impairment: Dose reduction to 100 mg once daily is required; standard dosing in severe hepatic impairment produces markedly elevated and prolonged drug exposure.
Active or unstable psychiatric conditions: Modafinil should not be initiated in patients with active psychosis, bipolar disorder in an acute phase, or severe untreated anxiety without psychiatric input and a clearly defined monitoring plan.
Take modafinil in the morning for narcolepsy and OSA indications, or approximately one hour before the shift begins for SWSD. Taking the medication later in the day will delay nighttime sleep onset and compound the risk of chronic sleep deprivation — the very condition the drug is prescribed to treat.
Maintain consistent daily hydration. Headache — the most common adverse effect — is substantially worsened by inadequate fluid intake. Patients should not rely on the medication's alerting effects as a substitute for adequate rest on nights when sleep is available.
Report any skin change immediately. Any new rash during the first several weeks of treatment warrants same-day medical contact and should not be monitored at home without clinical guidance.
Do not escalate the dose without physician guidance. If modafinil appears to be losing efficacy, this should be discussed with the prescriber. Unilateral dose increases substantially elevate adverse effect risk and carry no reliable therapeutic benefit above 400 mg per day.
Store securely. As a Schedule IV controlled substance, modafinil must be stored in a secure location inaccessible to children or other household members. Do not share the prescription.
Driving and operational safety: Until an individual patient's response to modafinil is established — particularly during the first days of treatment — caution should be exercised before driving, operating industrial machinery, or performing tasks where unexpected sedation or impaired judgment could cause harm.
In the United States, the legal path to modafinil is through a licensed physician consultation culminating in a valid prescription, which can be filled at any licensed U.S. pharmacy — in person or through a regulated telehealth platform. Generic modafinil is widely available and substantially less expensive than branded Provigil; the two are bioequivalent, and generic formulations are the standard of care in cost-conscious prescribing. Insurance coverage for generic modafinil is broadly available for FDA-approved indications.
For patients outside the United States — in Canada (Alertec), Australia (Modavigil), or across Europe (Modiodal) — the same fundamental requirements apply: a valid local prescription from a licensed physician and dispensing from a nationally licensed and regulated pharmacy. The markers of a legitimate pharmacy are consistent regardless of jurisdiction: a mandatory prescription requirement for controlled substances, verifiable licensing credentials, transparent dispensing records, and accountable contact information.
My Online Med Shop provides a verified range of modafinil and related wakefulness medications, sourced from verified pharmaceutical manufacturers, with free home delivery, discreet packaging, secure checkout, and 24/7 customer support. The full range of sleep and wakefulness disorder medications is available through the platform. Always consult your healthcare provider before starting any new prescription treatment.
Modafinil is technically classified as a wakefulness-promoting agent (eugeroic) rather than a traditional stimulant, though it shares dopaminergic mechanisms with stimulant drugs. Its broader, more selective multi-pathway action produces sustained, natural-feeling wakefulness without the intense euphoria, peripheral cardiovascular stimulation, or marked rebound fatigue associated with amphetamines. This pharmacological distinction underlies its Schedule IV rather than Schedule II classification, and its generally lower abuse potential compared to classical stimulants.
Modafinil is FDA-approved for three indications: narcolepsy, excessive daytime sleepiness in obstructive sleep apnea where residual sleepiness persists despite adequate CPAP therapy, and shift work sleep disorder. It is not FDA-approved for ADHD, though it is widely studied and prescribed off-label for this and other conditions under physician supervision.
Yes — this is one of the most important and underrecognized interactions associated with modafinil. The drug induces CYP3A4 liver enzymes, which accelerates the metabolism of all hormonal contraceptive methods — including combined oral pills, progestin-only pills, patches, implants, and hormonal IUDs — potentially reducing plasma levels enough to cause contraceptive failure. Patients of childbearing potential must use non-hormonal or barrier contraception throughout the treatment period and for a minimum of one full month after stopping modafinil.
Modafinil typically produces noticeable wakefulness-promoting effects within 30 to 60 minutes of oral administration, reaching peak plasma concentration at approximately 2 to 4 hours post-dose. The active effect is sustained for roughly 12 hours, reflecting the medication's half-life. Morning dosing is strongly recommended to avoid interference with nighttime sleep.
Modafinil carries a meaningfully lower risk of dependence and abuse compared to Schedule II stimulants — the basis for its Schedule IV classification. However, it is not without any dependence potential. Tolerance, psychological reliance, and withdrawal symptoms (predominantly fatigue, low mood, and impaired concentration following discontinuation) have been reported with extended high-dose use. At prescribed therapeutic doses under appropriate physician supervision, clinically significant dependence is uncommon but not impossible. Use should be limited to the prescribed indication, dose, and duration.
Modafinil is a racemic mixture of R- and S-enantiomers. Armodafinil (Nuvigil) is the purified R-enantiomer, active at approximately 50–75% of the modafinil dose. Armodafinil maintains higher plasma concentrations during the mid-to-late afternoon, while modafinil peaks earlier and declines more steeply. Both are FDA-approved for the same three indications and carry identical DEA scheduling. Patient preference, sleep schedule, and individual pharmacokinetic response typically determine which is more appropriate — a decision best made with physician guidance.
Any new skin rash during modafinil treatment requires immediate medical attention — on the same day it appears. Modafinil carries a documented risk of Stevens-Johnson Syndrome (SJS) and DRESS, both of which typically begin as what appears to be a mild rash. Do not take a wait-and-see approach. Discontinue the medication immediately and seek urgent clinical evaluation. Modafinil must not be restarted without explicit physician clearance after any dermatological reaction during treatment.
Modafinil does not carry the same FDA-mandated short-term restriction as Z-drug sleep medications. For approved chronic conditions such as narcolepsy, long-term use under physician supervision is a recognized and accepted treatment approach. However, prolonged use warrants periodic review: monitoring for cardiovascular effects, mood changes, any signs of tolerance or dependence, and ongoing confirmation that the benefit-risk balance remains favorable for the individual patient.
Modafinil occupies a unique and well-established position in the pharmacological management of excessive daytime sleepiness. Its multi-modal wakefulness-promoting mechanism, sustained 12–15 hour coverage, significantly lower abuse liability compared to classical stimulants, and FDA approval across three distinct indications have made it a cornerstone treatment option across more than two decades of clinical use.
For patients with narcolepsy, obstructive sleep apnea with residual daytime sleepiness, or shift work sleep disorder, modafinil — and its refined successor armodafinil — represent the preferred pharmacological approach in most clinical guidelines, with newer agents such as pitolisant and solriamfetol providing additional options for patients who do not tolerate or respond adequately to eugeroics.
Safe, effective modafinil use in 2026 rests on the same foundations it always has: a valid prescription from a licensed physician, sourcing from a regulated pharmacy, adherence to the prescribed dose and timing, clear awareness of the contraception interaction, and prompt reporting of any dermatological or psychiatric changes to the treating clinician. Patients who approach the medication within these parameters can expect sustained, clinically meaningful improvements in daytime alertness and functional capacity — outcomes that are well documented in the literature and experienced routinely by appropriately selected patients worldwide.
Buy Modafinil Online USA: Uses, Dosage & Safety Guide 2026
Buy Zopiclone Online
 Online.jpg "Buy Klonopin (Clonazepam) Online")
Buy Klonopin (Clonazepam) Online
Buy Sleeping Medicine Online